Histologic changes in superficial basal cell epithelioma and Bowen's disease by intralesional injection of recombinant interleukin 2: recombinant interleukin 2 may induce redifferentiation of malignant tumor cells in vivo.
Mihara
M
M
Nakayama
H
H
Nakamura
K
K
Morimura
T
T
Hagari
Y
Y
Shimao
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001913:Bowen's Disease / Q000473:pathology* / Q000628:therapy; D002280:Basal Cell Carcinoma / Q000473:pathology* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002454:Cell Differentiation; D004817:Epidermis / Q000473:pathology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy
D007376:Interleukin-2; D011994:Recombinant Proteins